End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
23.9 TWD | +1.70% | +4.82% | +6.94% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 423.4 | 579.7 | 749.5 | 569.8 | 517.4 | 520.8 |
Enterprise Value (EV) 1 | 281.7 | 431.7 | 597.5 | 370.1 | 351 | 478.1 |
P/E ratio | 15 x | 18.9 x | 25.3 x | 41.4 x | 54.2 x | -197 x |
Yield | 6.17% | 4.79% | 3.04% | 1.98% | 0.81% | - |
Capitalization / Revenue | 1.1 x | 1.39 x | 1.88 x | 1.82 x | 1.61 x | 1.86 x |
EV / Revenue | 0.73 x | 1.03 x | 1.5 x | 1.18 x | 1.09 x | 1.7 x |
EV / EBITDA | 6.08 x | 9.41 x | 14.1 x | 16.7 x | 14.4 x | 50.4 x |
EV / FCF | 9.82 x | 6.12 x | 19.7 x | 173 x | 13.5 x | -27.8 x |
FCF Yield | 10.2% | 16.3% | 5.07% | 0.58% | 7.38% | -3.59% |
Price to Book | 1.72 x | 2.31 x | 2.97 x | 1.84 x | 1.7 x | 1.78 x |
Nbr of stocks (in thousands) | 20,704 | 20,704 | 20,704 | 23,304 | 23,304 | 23,304 |
Reference price 2 | 20.45 | 28.00 | 36.20 | 24.45 | 22.20 | 22.35 |
Announcement Date | 4/2/19 | 4/14/20 | 3/16/21 | 3/8/22 | 3/6/23 | 3/14/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 384.4 | 417.5 | 398.1 | 312.6 | 321.9 | 280.5 |
EBITDA 1 | 46.33 | 45.87 | 42.28 | 22.23 | 24.44 | 9.48 |
EBIT 1 | 38.97 | 38.22 | 35.22 | 14.3 | 17.29 | -4.259 |
Operating Margin | 10.14% | 9.16% | 8.85% | 4.57% | 5.37% | -1.52% |
Earnings before Tax (EBT) 1 | 37.14 | 39.85 | 37.14 | 16.6 | 13.55 | -3.032 |
Net income 1 | 28.34 | 30.87 | 29.77 | 13.7 | 9.552 | -2.648 |
Net margin | 7.37% | 7.39% | 7.48% | 4.38% | 2.97% | -0.94% |
EPS 2 | 1.360 | 1.480 | 1.430 | 0.5900 | 0.4099 | -0.1136 |
Free Cash Flow 1 | 28.69 | 70.58 | 30.3 | 2.14 | 25.9 | -17.18 |
FCF margin | 7.46% | 16.91% | 7.61% | 0.68% | 8.05% | -6.12% |
FCF Conversion (EBITDA) | 61.93% | 153.86% | 71.66% | 9.63% | 106% | - |
FCF Conversion (Net income) | 101.24% | 228.62% | 101.76% | 15.62% | 271.17% | - |
Dividend per Share 2 | 1.262 | 1.341 | 1.102 | 0.4844 | 0.1800 | - |
Announcement Date | 4/2/19 | 4/14/20 | 3/16/21 | 3/8/22 | 3/6/23 | 3/14/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 142 | 148 | 152 | 200 | 166 | 42.8 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | 28.7 | 70.6 | 30.3 | 2.14 | 25.9 | -17.2 |
ROE (net income / shareholders' equity) | 12.1% | 12.4% | 11.8% | 4.87% | 3.11% | -1.04% |
ROA (Net income/ Total Assets) | 7.22% | 6.09% | 5.63% | 2.28% | 2.51% | -0.54% |
Assets 1 | 392.3 | 507 | 529.2 | 601.6 | 380.3 | 489.5 |
Book Value Per Share 2 | 11.90 | 12.10 | 12.20 | 13.30 | 13.00 | 12.50 |
Cash Flow per Share 2 | 6.800 | 8.270 | 7.740 | 8.570 | 6.810 | 8.070 |
Capex 1 | 9.25 | 8.45 | 5.91 | 4.38 | 26.9 | 27.7 |
Capex / Sales | 2.41% | 2.02% | 1.49% | 1.4% | 8.34% | 9.89% |
Announcement Date | 4/2/19 | 4/14/20 | 3/16/21 | 3/8/22 | 3/6/23 | 3/14/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+6.94% | 17.17M | |
+51.85% | 57.87B | |
+40.94% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- 6661 Stock
- Financials Welgene Biotech Co.,Ltd.